Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRB 701 (Primary)
  • Indications Cervical cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Corbus Pharmaceuticals

Most Recent Events

  • 03 Jun 2025 Number of Arms changed from 11 to 15
  • 03 Jun 2025 Planned number of patients changed from 420 to 348.
  • 06 May 2025 According to a Corbus Pharmaceuticals media release, dose escalation data from this trial was presented at ASCO GU. Dose optimization is ongoing, with dosing at 2.7 mg/kg and 3.6 mg/kg cohorts, and determination of the recommended Phase 2 dose (RP2D) is expected in Q4 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top